PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical Lung Cancer10.1016/j.cllc.2016.05.0012016176528-534Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and AlectinibSatomi Watanabe, Hidetoshi Hayashi, Kunio Okamoto, Kimiko Fujiwara, Yoshikazu Hasegawa, Hiroyasu Kaneda, Kaoru Tanaka, Masayuki Takeda, Kazuhiko Nakagawahttps://api.elsevier.com/content/article/PII:S1525730416301061?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730416301061?httpAccept=text/plain
The Korean Journal of Internal Medicine10.3904/kjim.2018.01120193451116-1124Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancerChan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heohttp://kjim.org/upload/kjim-2018-011.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2018.011, http://kjim.org/upload/kjim-2018-011.pdf
Lung Cancer: Targets and Therapy10.2147/lctt.s99303201683Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesMarie Wislez, Etienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranelhttps://www.dovepress.com/getfile.php?fileID=30953
Clinical Lung Cancer10.3816/clc.2011.n.008201112156-61Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib TherapyKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Tadashi Mio, Michiaki Mishimahttps://api.elsevier.com/content/article/PII:S1525730411700584?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411700584?httpAccept=text/plain
BMC Cancer10.1186/s12885-016-2636-z2016161Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgiahttp://link.springer.com/content/pdf/10.1186/s12885-016-2636-z.pdf, http://link.springer.com/article/10.1186/s12885-016-2636-z/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12885-016-2636-z, http://link.springer.com/content/pdf/10.1186/s12885-016-2636-z.pdf
Journal of Cancer Research and Clinical Oncology10.1007/s00432-014-1617-320141405839-848Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancerMasayuki Aboshi, Masayuki Kaneko, Mamoru Narukawahttp://link.springer.com/article/10.1007/s00432-014-1617-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00432-014-1617-3.pdf, http://link.springer.com/content/pdf/10.1007/s00432-014-1617-3
Clinical Lung Cancer10.1016/j.cllc.2018.11.0102019202e133-e136Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose BrigatinibMandy R. Sakamoto, Justin M. Honce, Deborah L. Lindquist, D. Ross Camidgehttps://api.elsevier.com/content/article/PII:S1525730418303061?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730418303061?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2016.05.0062016176474-482Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung CancerAlexios Matikas, Nikolaos Kentepozidis, Vassilis Georgoulias, Athanasios Kotsakishttps://api.elsevier.com/content/article/PII:S1525730416301115?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730416301115?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2016.04.00620169743-47Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancerTatsuya Yoshida, Yuko Oya, Kosuke Tanaka, Junichi Shimizu, Yoshitsugu Horio, Hiroaki Kuroda, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabehttps://api.elsevier.com/content/article/PII:S0169500216302768?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500216302768?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2019.06.0212019205e555-e559Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung CancerJun Sakakibara-Konishi, Hidenori Kitai, Yasuyuki Ikezawa, Yutaka Hatanaka, Takaaki Sasaki, Ryohei Yoshida, Shinichi Chiba, Shingo Matsumoto, Koichi Goto, Hidenori Mizugaki, Naofumi Shinagawahttps://api.elsevier.com/content/article/PII:S152573041930172X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S152573041930172X?httpAccept=text/plain